Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.

Tytuł:
Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Autorzy:
Li J; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Yang G; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Cai Q; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Wang Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Xu Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Zhang R; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Lang Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Cai X; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Źródło:
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Sep; Vol. 110, pp. 179-186. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Hamilton, ON : Elsevier
Original Publication: Hamilton, ON : Decker, c1996-
MeSH Terms:
Antitubercular Agents*/adverse effects
Tuberculosis, Multidrug-Resistant*/drug therapy
China ; Diarylquinolines/adverse effects ; Humans
Contributed Indexing:
Keywords: Bedaquiline; Multidrug-resistant tuberculosis; QTc prolongation; Serum concentration monitoring
Substance Nomenclature:
0 (Antitubercular Agents)
0 (Diarylquinolines)
78846I289Y (bedaquiline)
Entry Date(s):
Date Created: 20210722 Date Completed: 20210928 Latest Revision: 20210928
Update Code:
20240105
DOI:
10.1016/j.ijid.2021.07.038
PMID:
34293490
Czasopismo naukowe
Objectives: To determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring and to identify factors associated with QTc prolongation occurring during treatment.
Methods: Data were collected from 35 patients who received treatment regimens containing bedaquiline for MDR-TB from May 2018 to December 2020. Blood samples were collected, and serum concentrations of bedaquiline were measured using high-performance liquid chromatography-mass spectrometry.
Results: After completing the 24-week bedaquiline treatment course, 80.0% of the patients' sputum cultures turned negative. The median time to sputum culture conversion was 75.5 days (interquartile range 52-126 days). The mean serum concentration of bedaquiline was 0.586 ± 0.288 µg/ml during treatment and 0.205 ± 0.145 µg/ml at 16 weeks after bedaquiline discontinuation. Bedaquiline remained detectable 52 weeks after discontinuation. Combination with clofazimine during bedaquiline treatment significantly increased cardiac QTc prolongation. When QTc prolongation occurred, serum potassium levels decreased by 10.71% from baseline, while serum sodium levels increased by 1.07% from baseline.
Conclusions: Good treatment outcomes were obtained with bedaquiline treatment in Chinese patients with MDR-TB. Combination with clofazimine increased the risk of QTc prolongation. Serum electrolytes (potassium and sodium) should be measured regularly during treatment of MDR-TB with regimens containing bedaquiline.
(Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies